Business
Helix retains leading health care communications firm
Helix retains leading health care communications firm.
About this update from Helix Biopharma Corp.
[{"type":"text","content":"\n\n\n\n\nAURORA, ON, June 5 /CNW/ - Helix BioPharma Corp. (TSX, FSE: \"HBP\") today\nannounced that it has entered into an agreement with U.S.-based Noonan Russo,\na division of Euro RSCG Life PR, in order to increase the public profile of\nHelix among the scientific research, pharmaceutical and investment communities\nin the United States, as well as to provide Helix's existing U.S. shareholders\nwith timely information related to Helix.\nThis initiative is being undertaken as the Company continues to engage\nU.S.-based scientific, technical and research services for its lead product\ndevelopment programs, and begins to explore the possibility of pursuing\nadditional strategic partnerships to support its growing product development\nobjectives. This initiative is also intended to introduce Helix to the U.S.\ncapital markets, with a view to obtaining institutional support for possible\nfuture financings in the U.S.\nThis agreement with Noonan Russo will complement Helix's Canadian\ncommunications strategy currently managed by The Equicom Group Inc.\n\nAbout Noonan Russo\n\nNoonan Russo, a division of Euro RSCG Life PR, is a leading healthcare\npublic and investor relations consultancy delivering strategic programs that\nhelp transform companies into key leaders in their sectors. The agency's\nclients span the range of large pharmaceutical companies, to midsize and \nstart-up biotech, medical device and healthcare companies.\nNoonan Russo has headquarters in New York City and offices in San Diego,\nCalifornia, Washington, DC, London, UK, and Paris, France.\n\nAbout Helix BioPharma Corp.\n\nHelix BioPharma Corp. is a biopharmaceutical company specializing in the\nfield of cancer therapy. The Company is actively developing innovative\nproducts for the prevention and treatment of cancer based on its proprietary\ntechnologies. Helix's product development initiatives include its Topical\nInterferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed\non the TSX under the symbol \"HBP\", and quoted on the Frankfurt, Berlin, Munich\nand Stuttgart Stock Exchanges under the same symbol.\n\nThe Toronto and Frankfurt Stock Exchanges have not reviewed and do not\naccept responsibility for the adequacy or accuracy of the content of this News\nRelease. This News Release contains certain forward-looking statements\nregarding the...